Our results showed that prostate cancer patients had an average serum TIMP-1 concentration of 351.4 ng/ml, significantly higher than the average concentration of 211.0 ng/ml seen in men without prostate cancer recruited from a urology clinic (p<0.001) (Figure 1A). This evidence concerns the gene TIMP1 and prostate carcinoma.